Conjunctivitis (Pink Eye) Treatments

Find Conjunctivitis (Pink Eye) Treatments

Generic Name

CycloSPORINE

Brand Names

CEQUA, Sandimmune, Restasis MultiDose, Verkazia, Neoral, Restasis, Gengraf, VEVYE

FDA approval date: November 14, 1983

Classification: Calcineurin Inhibitor Immunosuppressant

Form: Injection, Emulsion, Capsule, Solution

What is CEQUA (CycloSPORINE)?

Kidney, Liver, and Heart Transplantation Cyclosporine capsules is indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. Cyclosporine capsules has been used in combination with azathioprine and corticosteroids. Rheumatoid Arthritis Cyclosporine capsules is indicated for the treatment of patients with severe active, rheumatoid arthritis where the disease has not adequately responded to methotrexate. Cyclosporine capsules can be used in combination with methotrexate in rheumatoid arthritis patients who do not respond adequately to methotrexate alone. Psoriasis Cyclosporine capsules is indicated for the treatment of adult, nonimmunocompromised patients with severe , recalcitrant, plaque psoriasis who have failed to respond to at least one systemic therapy or in patients for whom other systemic therapies are contraindicated or cannot be tolerated. While rebound rarely occurs, most patients will experience relapse with cyclosporine capsules as with other therapies upon cessation of treatment.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

Phase II Study of Horse Anti-Thymocyte Globulin (hATG), Cyclosporine, Methylprednisolone, and GCSF (Filgrastim or Pegfilgrastim) in Patients With Aplastic Anemia (AA), or Low/Int-1 Risk Myelodysplastic Syndrome (MDS)

Who is this study for: Patients with Myelodysplastic Syndrome

Enrollment Status: Recruiting

Publish Date: April 15, 2026

Intervention Type: Biological, Drug

Study Drugs: Cyclosporine, Filgrastim, Methylprednisolone, PEG-Filgrastim, Anti-Thymocyte Globulin

Study Phase: Phase 2

Summary: This phase II trial studies methylprednisolone, horse anti-thymocyte globulin, cyclosporine, filgrastim, and/or pegfilgrastim or pegfilgrastim biosimilar in treating patients with aplastic anemia or low or intermediate-risk myelodysplastic syndrome. Horse anti-thymocyte globulin is made from horse blood and targets immune cells known as T-lymphocytes. Since T-lymphocytes are believed to be involve...

Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

Who is this study for: Patients with Nephrotic Syndrome, Proteinuria, Autoimmune Disease

Enrollment Status: Recruiting

Publish Date: April 08, 2026

Intervention Type: Drug

Study Drugs: Rituximab Infusion, Oral Cyclosporine

Study Phase: Phase 2

Background: * Membranous nephropathy is associated with damage to the walls of the glomeruli, the small blood vessels in the kidneys that filter waste products from the blood. This damage causes leakage of blood proteins into the urine and is associated with low blood protein levels, high blood cholesterol values, and swelling of the legs. These problems can decrease or go away without treatment in about 25 p...

A Multicenter, Randomized, Open-Label Study to Analyze the Efficacy of Unrelated Cord Blood Combined With Haploidentical Stem Cell Transplantation in Patients With Aplastic Anemia

Enrollment Status: Recruiting

Publish Date: March 30, 2026

Intervention Type: Procedure

Study Phase: Not Applicable

Summary: Aplastic anemia (AA) is a bone marrow failure disorder characterized by pancytopenia and hypoplastic bone marrow caused by the decrease of hematopoietic stem cells. The pathogenesis of AA is complex and involves an abnormal hematopoietic microenvironment, hematopoietic stem cell/progenitor cell deficiencies and immunity disorders. Currently, the standard treatment for AA includes immunosuppressive...

View All Clinical Trials